{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Genotyping&page=9", "query": { "condition": "Genotyping", "page": 9 }, "page_size": 10 }, "pagination": { "page": 9, "page_size": 10, "total_count": 512, "total_pages": 52, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Genotyping&page=10&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Genotyping&page=8&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-25T18:59:30.586Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT01500772", "title": "Alisporivir With PEG and RBV in Protease Inhibitor (PI) Treatment Failure Patients With Chronic Hepatitis C", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Hepatitis C" ], "interventions": [ { "name": "Alisporivir", "type": "DRUG" }, { "name": "Peginterferon alfa-2a", "type": "DRUG" }, { "name": "Ribavirin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Debiopharm International SA", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "18 Years to 70 Years" }, "enrollment_count": 6, "start_date": "2012-03", "completion_date": "2012-05", "has_results": true, "last_update_posted_date": "2016-08-01", "last_synced_at": "2026-10-25T18:59:30.586Z", "location_count": 26, "location_summary": "Phoenix, Arizona • Bakersfield, California • Los Angeles, California + 19 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Bakersfield", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Palo Alto", "state": "California" }, { "city": "Sacramento", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01500772" }, { "nct_id": "NCT01701401", "title": "Safety and Efficacy of Ledipasvir/Sofosbuvir Fixed-Dose Combination (FDC) With and Without Ribavirin for the Treatment of HCV", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Chronic Hepatitis C Virus" ], "interventions": [ { "name": "LDV/SOF", "type": "DRUG" }, { "name": "RBV", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Gilead Sciences", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 870, "start_date": "2012-09", "completion_date": "2014-04", "has_results": true, "last_update_posted_date": "2018-11-16", "last_synced_at": "2026-10-25T18:59:30.586Z", "location_count": 53, "location_summary": "Birmingham, Alabama • La Jolla, California • Long Beach, California + 50 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "La Jolla", "state": "California" }, { "city": "Long Beach", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Palo Alto", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01701401" }, { "nct_id": "NCT05183828", "title": "Effect of HSD3B1 (1245C) Gene Mutation on Treatment of Stage I-III Breast Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Anatomic Stage I Breast Cancer AJCC v8", "Anatomic Stage II Breast Cancer AJCC v8", "Anatomic Stage III Breast Cancer AJCC v8", "Breast Adenocarcinoma", "Invasive Breast Carcinoma of No Special Type" ], "interventions": [ { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Letrozole", "type": "DRUG" }, { "name": "Questionnaire Administration", "type": "OTHER" } ], "intervention_types": [ "PROCEDURE", "DRUG", "OTHER" ], "sponsor": "University of Washington", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 62, "start_date": "2022-01-23", "completion_date": "2026-05-13", "has_results": false, "last_update_posted_date": "2026-06-04", "last_synced_at": "2026-10-25T18:59:30.586Z", "location_count": 1, "location_summary": "Seattle, Washington", "locations": [ { "city": "Seattle", "state": "Washington" } ], "official_url": "https://clinicaltrials.gov/study/NCT05183828" }, { "nct_id": "NCT01194037", "title": "A Phase 1b/2a Study of SC Hanferon™ in Combination With Ribavirin in Treatment-naïve Subjects With Genotype 1 Hepatitis C", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Chronic Hepatitis C Infection", "Genotype 1" ], "interventions": [ { "name": "recombinant variant of interferon-alpha 2b", "type": "DRUG" }, { "name": "Peginterferon alfa-2a", "type": "DRUG" }, { "name": "Ribavirin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "HanAll BioPharma Co., Ltd.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 30, "start_date": "2011-06-23", "completion_date": "2011-11-28", "has_results": false, "last_update_posted_date": "2025-04-22", "last_synced_at": "2026-10-25T18:59:30.586Z", "location_count": 6, "location_summary": "Los Angeles, California • National City, California • Miami, Florida + 3 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "National City", "state": "California" }, { "city": "Miami", "state": "Florida" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Lexington", "state": "Kentucky" } ], "official_url": "https://clinicaltrials.gov/study/NCT01194037" }, { "nct_id": "NCT00585312", "title": "Trial In Pediatric Patients With Familial Adenomatous Polyposis (FAP)", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Adenomatous Polyposis Coli" ], "interventions": [ { "name": "Celecoxib", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Pfizer's Upjohn has merged with Mylan to form Viatris Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "10 Years", "maximum_age": "17 Years", "sex": "ALL", "summary": "10 Years to 17 Years" }, "enrollment_count": 106, "start_date": "2006-09", "completion_date": "2013-10", "has_results": true, "last_update_posted_date": "2021-02-21", "last_synced_at": "2026-10-25T18:59:30.586Z", "location_count": 23, "location_summary": "Chicago, Illinois • Ann Arbor, Michigan • Omaha, Nebraska + 16 more", "locations": [ { "city": "Chicago", "state": "Illinois" }, { "city": "Ann Arbor", "state": "Michigan" }, { "city": "Omaha", "state": "Nebraska" }, { "city": "New York", "state": "New York" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT00585312" }, { "nct_id": "NCT00420784", "title": "A Study of Telaprevir (VX-950), Pegasys and Copegus in Hepatitis C (PROVE3)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Hepatitis C" ], "interventions": [ { "name": "Telaprevir", "type": "DRUG" }, { "name": "Ribavirin", "type": "DRUG" }, { "name": "Pegylated Interferon Alfa 2a", "type": "DRUG" }, { "name": "Matching Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Vertex Pharmaceuticals Incorporated", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "18 Years to 70 Years" }, "enrollment_count": 465, "start_date": "2007-02", "completion_date": "2009-04", "has_results": true, "last_update_posted_date": "2014-08-05", "last_synced_at": "2026-10-25T18:59:30.586Z", "location_count": 41, "location_summary": "Birmingham, Alabama • Los Angeles, California • San Diego, California + 35 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "San Diego", "state": "California" }, { "city": "San Diego", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00420784" }, { "nct_id": "NCT01257269", "title": "Genotype and Phenotype Correlation in Hereditary Thrombotic Thrombocytopenic Purpura (Upshaw-Schulman Syndrome)", "overall_status": "RECRUITING", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Thrombotic Thrombocytopenic Purpura", "Congenital Thrombotic Thrombocytopenic Purpura", "Familial Thrombotic Thrombocytopenic Purpura", "Thrombotic Thrombocytopenic Purpura, Congenital", "Upshaw-Schulman Syndrome" ], "interventions": [ { "name": "Observation", "type": "OTHER" } ], "intervention_types": [ "OTHER" ], "sponsor": "Insel Gruppe AG, University Hospital Bern", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": null, "sex": "ALL", "summary": "Not listed" }, "enrollment_count": 450, "start_date": "2006-10", "completion_date": "2030-10", "has_results": false, "last_update_posted_date": "2023-10-11", "last_synced_at": "2026-10-25T18:59:30.586Z", "location_count": 1, "location_summary": "Oklahoma City, Oklahoma", "locations": [ { "city": "Oklahoma City", "state": "Oklahoma" } ], "official_url": "https://clinicaltrials.gov/study/NCT01257269" }, { "nct_id": "NCT01987453", "title": "Ledipasvir/Sofosbuvir Fixed-Dose Combination ± Ribavirin in Participants With Chronic Genotype 1 HCV Who Participated in a Prior Gilead-Sponsored HCV Treatment Study", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "HCV Infection" ], "interventions": [ { "name": "LDV/SOF", "type": "DRUG" }, { "name": "RBV", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Gilead Sciences", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 100, "start_date": "2014-07", "completion_date": "2015-11", "has_results": true, "last_update_posted_date": "2018-11-19", "last_synced_at": "2026-10-25T18:59:30.586Z", "location_count": 39, "location_summary": "Beverly Hills, California • La Jolla, California • Los Angeles, California + 34 more", "locations": [ { "city": "Beverly Hills", "state": "California" }, { "city": "La Jolla", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01987453" }, { "nct_id": "NCT01183494", "title": "A Genotype-guided Study of Irinotecan Administered in Combination With 5-fluorouracil/Leucovorin (FOLFIRI) and Bevacizumab in Advanced Colorectal Cancer Patients", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Metastatic Colorectal Cancer" ], "interventions": [ { "name": "FOLFIRI, Avastin, Irinotecan", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Chicago", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 17, "start_date": "2009-12-12", "completion_date": "2017-06-02", "has_results": false, "last_update_posted_date": "2019-04-22", "last_synced_at": "2026-10-25T18:59:30.586Z", "location_count": 1, "location_summary": "Chicago, Illinois", "locations": [ { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT01183494" }, { "nct_id": "NCT02194998", "title": "Evaluating the Safety and Effectiveness of Interferon-Free Treatment of Hepatitis C Virus Infection in HIV-Coinfected Adults on Antiretroviral Therapy", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "HIV Infections", "Hepatitis C" ], "interventions": [ { "name": "Paritaprevir/ritonavir/ombitasvir (PTV/r/OBT)", "type": "DRUG" }, { "name": "Dasabuvir (DSV)", "type": "DRUG" }, { "name": "Ribavirin (RBV)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "18 Years to 70 Years" }, "enrollment_count": 46, "start_date": "2015-09-16", "completion_date": "2018-11-13", "has_results": true, "last_update_posted_date": "2021-11-04", "last_synced_at": "2026-10-25T18:59:30.586Z", "location_count": 15, "location_summary": "Birmingham, Alabama • Los Angeles, California • Aurora, Colorado + 12 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Los Angeles", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT02194998" } ] }